Cancer Stem Cell News Volume 12.00 | Jan 4 2023

    0
    14








    2023-01-04 | CSCN 12.00


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.00 – 4 January, 2023
    TOP STORY

    Tumor Cell-Intrinsic CD96 Mediates Chemoresistance and Cancer Stemness by Regulating Mitochondrial Fatty Acid β-Oxidation

    Scientists found that CD96 was frequently expressed in tumor cells from clinical breast cancer samples. The CD96+ cancer cell subpopulations exhibited features of both breast CSCs and chemoresistance.
    [Advanced Science]

    Full Article
    The Immunology Podcast is here. Find it wherever you get your podcasts.
    PUBLICATIONSRanked by the impact factor of the journal

    Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells

    Researchers reported a nanotherapeutic strategy based on MnOx-loaded polydopamine nanobombs with chemodynamic, photodynamic, photothermal, and biodegradation properties to inhibit CSCs and non-CSCs concurrently.
    [Small]

    Abstract

    Deubiquitinating Enzyme Josephin-2 Stabilizes PHGDH to Promote a Cancer Stem Cell Phenotype in Hepatocellular Carcinoma

    Scientists designed a study to reveal the effect and underlying mechanism of Josephin-2, a relatively newly defined deubiquitinating enzyme, in hepatocellular carcinoma progression.
    [Genes & Genomics]

    Abstract

    Genetic Profiling of Different Phenotypic Subsets of Breast Cancer Stem Cells (BCSCs) in Breast Cancer Patients

    Investigators characterized BCSCs through the genetic profiling of different BCSCs phenotypic subsets to determine their related genetic pathways.
    [Cancer Cell International]

    Full Article

    Transcription Factor YY1 Mediates Self-Renewal of Glioblastoma Stem Cells through Regulation of the SENP1/METTL3/MYC Axis

    The authors investigated the regulatory effect of the SUMO-specific protease 1 (SENP1)/methyltransferase-like 3 (METTL3)/MYC axis on the self-renewal of glioblastoma stem cells mediated by transcription factor Yin Yang 1 (YY1).
    [Cancer Gene Therapy]

    Abstract

    The Heterogeneous Cellular States of Glioblastoma Stem Cells Revealed by Single Cell Analysis

    Scientists leveraged single-cell transcriptome sequencing data of six independent glioblastoma cohorts from public databases, and combined lineage and stemness features to identify primary glioblastoma stem cells.
    [Stem Cells]

    AbstractGraphical Abstract

    Significance of Oct-4 Transcription Factor as a Pivotal Therapeutic Target for CD44+/24 Mammary Tumor Initiating Cells: Aiming at the Root of the Recurrence

    Researchers attempted to identify previously unrecognized CSC survival factors that could be used as druggable targets for breast CSCs apoptosis regulators isolated from the triple-negative breast cancer line.
    [Cell Biology International]

    Abstract

    Nanobodies Targeting ABCC3 for Immunotargeted Applications in Glioblastoma

    High expression of ATP Binding Cassette subfamily C member 3 (ABCC3) was restricted to glioblastoma, with negligible levels in healthy brain tissue, and further correlated with tumor grade and stemness markers.
    [Scientific Reports]

    Full Article

    CPSF4 Promotes Tumor-Initiating Phenotype by Enhancing VEGF/NRP2/TAZ Signaling in Lung Cancer

    The authors demonstrated that cleavage and polyadenylation specificity factor 4 (CPSF4) promoted tumor-initiating phenotype and conferred chemoresistance to paclitaxel both in vitro and in vivo.
    [Medical Oncology]

    Abstract
    Survey results on the needs and challenges in the human pluripotent stem cell field
    REVIEWS

    Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies

    Investigators provide an overview of the available methods for assessing the efficacy of whole CSC-based vaccines on tumor development, metastasis, and survival rate.
    [Stem Cells]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    STEMCELL Technologies President and CEO Dr. Allen Eaves Appointed to the Order of Canada

    STEMCELL Technologies announced that its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honorable Mary Simon, the Governor General of Canada.
    [STEMCELL Technologies]

    Press Release
    FEATURED EVENT

    ESMO Targeted Anticancer Therapies Congress 2023

    March 6 – 8, 2023
    Paris, France

    > See All Events

    JOB OPPORTUNITIES

    PhD Positions – Life Sciences and Bioinformatics

    University Medical Center Freiburg – Freiburg, Germany

    Research Specialist – Microbiology, Tumor, and Cell Biology

    Karolinska Institutet – Solna, Sweden

    Associate Research Scientist – Stem Cells and Tissue Engineering

    Columbia University – New York, New York, United States

    Principal Investigator – Division of Cellular and Gene Therapies

    US FDA – Silver Spring, Maryland, United States

    Postdoctoral Position – Blood Cancer Institute

    Albert Einstein College of Medicine – Bronx, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter